Methane

Methane

SCHEMBL506242

C.O=C(O)Cc1ccc2c(c1)[nH]c1ccc(Cl)cc12

nearest known ligand 0.68

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.67
MAPT P10636 2/20 0.67
KMT2A Q03164 2/20 0.67
KDM4E B2RXH2 2/20 0.67
ALDH1A1 P00352 2/20 0.67
HPGD P15428 1/20 0.67
HSD17B10 Q99714 1/20 0.67
PTGS2 P35354 2/20 0.54
ABCC4 O15439 1/20 0.54
C5 P01031 1/20 0.54
PTGS1 P23219 1/20 0.54
PDE4D Q08499 1/20 0.54
SIRT1 Q96EB6 3/20 0.44
SIRT2 Q8IXJ6 1/20 0.44
CHUK O15111 1/20 0.43
CA2 P00918 1/20 0.43
PARP1 P09874 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31324164 0.99 MEN1 (0.69) MEN1MAPTKMT2AKDM4EALDH1A1
SCHEMBL31324193 0.93 MEN1 (0.73) MEN1MAPTKMT2AKDM4EALDH1A1
SCHEMBL31324199 0.91 MEN1 (0.81) MEN1MAPTKMT2AKDM4EALDH1A1
SCHEMBL10068095 0.84 MAPT (0.69) MEN1MAPTKMT2AKDM4EALDH1A1
Methane SCHEMBL28656788 0.84 PTGS2 (0.50) MEN1MAPTKMT2AKDM4EALDH1A1
SCHEMBL31324154 0.82 PTGS2 (0.51) MEN1MAPTKMT2AKDM4EALDH1A1
SCHEMBL11018311 0.82 PTGS2 (0.51) MEN1MAPTKMT2AKDM4EALDH1A1
Methane SCHEMBL8206725 0.82 KDM4E (0.72) MEN1MAPTKMT2AKDM4EALDH1A1
Methane SCHEMBL28638234 0.82 ALOX15 (0.50) MEN1MAPTKMT2AALDH1A1HPGD
SCHEMBL11268534 0.82 PTGS2 (0.60) MEN1MAPTKMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102388014-A Synthesis method of chiral alpha-aryl propionic acid derivative DSM IP ASSETS BV 2012-03-21 CN claimed
US-20120029226-A1 METHOD FOR THE SYNTHESIS OF CHIRAL ALPHA-ARYL PROPIONIC ACID DERIVATIVES DSM IP ASSETS B.V. (NL) 2012-02-02 US claimed
EP-0970694-B1 Use of carprofen and derivatives therof for treating or preventing articular degeneration PFIZER PROD INC (US) 2006-07-05 EP claimed
WO-2006042381-A1 ANTI-INFLAMMATORY PREPARATION PARNELL LABORATORIES (AUST) PTY LIMITED (AU) 2006-04-27 WO claimed
US-20030212123-A1 COX-2 selective carprofen for treating pain and inflammation in dogs PFIZER INC. 2003-11-13 US claimed
US-6506785-B2 Establishing the status of the mammal as presently or prospectively being in early stages of degeneration of articular cartilage or subchondral bone in one or more joinsts, administering a xanthine chondroprotective compound PFIZER, INC. 2003-01-14 US claimed
US-20030008911-A1 Treating or preventing the early stages of degeneration of articular cartilage or subchondral bone in mammals using carprofen and derivatives EVANS NIGEL A (US) 2003-01-09 US claimed
US-20010002401-A1 TREATING OR PREVENTING THE EARLY STAGES OF DEGENERATION OF ARTICULAR CARTILAGE OR SUBCHONDRAL BONE IN MAMMALS USING CARPROFEN AND DERIVATIVES PFIZER INC. 2001-05-31 US claimed
CN-1255059-A COX-2 selective carprofen for treating pain and inflammation in dogs PFIZER (US) 2000-05-31 CN claimed
EP-0988034-A1 COX-2 SELECTIVE CARPROFEN FOR TREATING PAIN AND INFLAMMATION IN DOGS PFIZER INC. (US) 2000-03-29 EP claimed
EP-0970694-A2 Use of carprofen and derivatives therof for treating or preventing articular degeneration Pfizer Products Inc. (US) 2000-01-12 EP claimed
WO-1998050033-A1 COX-2 SELECTIVE CARPROFEN FOR TREATING PAIN AND INFLAMMATION IN DOGS PFIZER INC. (US) 1998-11-12 WO claimed
CN-86103879-A Provide the method for 2-arylpropionic acid for oneself 1987-04-08 CN claimed
WO-2025029805-A2 HEMOSTATIC COMPOSITIONS AND METHODS PMIDG, LLC (US) 2025-02-06 WO disclosed
CN-111808011-B High penetration composition and its application 泰飞尔生物医药(苏州)有限公司 2024-02-27 CN disclosed
WO-2024030437-A1 FUNCTIONALIZED AND CROSSLINKED POLYMER METHODS AND COMPOSITIONS PMIDG, LLC (US) 2024-02-08 WO disclosed
EP-0110671-A1 Preparation of optically active alpha-arylalkanoic acids and precursors thereof SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) 1984-06-13 EP disclosed
EP-0081993-A2 Optically active alpha-substituted aryl ketones, their preparation and their use in preparing alpha-arylalkanoic acids SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) 1983-06-22 EP disclosed
US-4362738-A ANTIINFLAMMATORIES DR. KARL THOMAE GMBH (DE) 1982-12-07 US disclosed
EP-0064394-A1 Manufacture of alpha-arylalkanoic acids and precursors SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) 1982-11-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030212123-A1 COX-2 selective carprofen for treating pain and inflammation in dogs PTGES2, PTGER2, PTGS2 MEN1 4733/4885MAPT 4380/4885KMT2A 1486/4885
US-20010002401-A1 TREATING OR PREVENTING THE EARLY STAGES OF DEGENERATION OF ARTICULAR CARTILAGE OR SUBCHONDRAL BONE IN MAMMALS USING CARPROFEN AND DERIVATIVES IGFBP1, IGFBP5, MMP1 MEN1 4522/4885MAPT 4791/4885KMT2A 4719/4885
US-20030008911-A1 Treating or preventing the early stages of degeneration of articular cartilage or subchondral bone in mammals using carprofen and derivatives IGFBP1, MMP1, IGFBP5 MEN1 4610/4885MAPT 4832/4885KMT2A 4651/4885
US-20120029226-A1 METHOD FOR THE SYNTHESIS OF CHIRAL ALPHA-ARYL PROPIONIC ACID DERIVATIVES GRIA1, GRIA3, GRIA2 MEN1 3864/4885MAPT 2292/4885KMT2A 3494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.